Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Nov 19;218(3):e20201993. doi: 10.1084/jem.20201993

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Schäfer et al.

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Figure 4. — Antibody combinations increase in vivo potency. SARS-CoV-2 MA lung titer following antibody prophylaxis with isotype control (16 mg/kg) or combinations of C135-LS + C121-LS or C135-LS + C144-LS mixed at a ratio of 1:1 for combined dose levels of 16, 5.3, or 1.8 mg/kg. Antibodies were delivered intraperitoneally 12 h before infection with 10⁵ PFU of SARS-CoV-2 MA. Single antibodies C121-LS, C135-LS, or C144-LS were similarly administered at 8 mg/kg (n = 8/antibody). Combined data from two independent experiments are shown. For 16-mg/kg groups, n = 14 or 15 mice, and all other groups were 9 or 10 mice/group. The line is at the geometric mean, and each symbol represents the titer for a single animal. Asterisks indicate statistical differences compared with isotype control by one-way ANOVA with a Dunnett’s multiple comparison test (****, P < 0.0001) or Kruskal-Wallis test with a Tukey’s multiple comparison test (*, P = 0.02–0.04; ***, P = 0.0002; ****, P < 0.0001). LOD, limit of detection.